News

NEW YORK, NY – JANUARY 7, 2021 - Royalty Pharma plc (Nasdaq: RPRX) today announced that management will present at the 39 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 10:50 a.m. EST. Investors, analysts, members of the media and the general public are invited to

NEW YORK, NY, December 22, 2020 – Royalty Pharma plc (Nasdaq: RPRX) today announced charitable contributions totaling $7,660,000 to support important COVID-19 research at The Rockefeller University, Mount Sinai Health System and Columbia University. This amount includes donations from Royalty

NEW YORK, NY, December 21, 2020 – Royalty Pharma (Nasdaq: RPRX) today announced a charitable contribution by Royalty Pharma in the amount of $1,000,000 to Mount Sinai Health System. The funds will be used to support: Mount Sinai’s Center for Post-COVID Care (CPCC) and Post-COVID Registry:   Royalty

NEW YORK , Dec. 21, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an expansion of its leadership team: Jim Reddoch , PhD will assume increased responsibilities with a new role of Chief Scientific Officer, which is in addition to his position as Co-Head of Research &

NEW YORK, NY, December 17, 2020 – Royalty Pharma (Nasdaq: RPRX) and The Rockefeller University announced generous gifts totaling $5,760,000 from Royalty Pharma and Pablo and Almudena Legorreta. Half of the gift will be donated by Royalty Pharma and the other half by Pablo and Almudena Legorreta

NEW YORK, NY and RESEARCH TRIANGLE PARK, N.C, December 7, 2020 – Royalty Pharma (Nasdaq: RPRX), BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and Athyrium Capital Management, LP today announced transactions totaling $325 million in funding for BioCryst, with $250 million available at closing, to

NEW YORK, NY, November 2, 2020 - Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement to acquire the residual royalty interest in Vertex Pharmaceuticals, Inc.’s cystic fibrosis (CF) treatments owned by the Cystic Fibrosis Foundation. The agreement includes an upfront payment of $575

NEW YORK , Oct. 20, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (the “Company”) (Nasdaq: RPRX) announced today the closing of the secondary offering of 17,343,037 shares of its Class A ordinary shares by selling shareholders in an underwritten public offering at a price to the public of $42.00 per

NEW YORK , Oct. 19, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma (Nasdaq: RPRX) today announced that it will report its third quarter 2020 financial results on Wednesday, November 11, 2020 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00